Amneal Pharmaceuticals, Inc. announced that Jeff George, John Kiely and Shlomo Yanai have been appointed to the company’s Board of Directors, effective as of December 14, 2019. These three new independent directors bring to Amneal extensive records of overseeing growth and creating value in the pharmaceutical and healthcare industries. Jeff George has nearly 20 years of global healthcare and corporate leadership experience across North America, Europe and emerging markets. He currently serves as Managing Partner of Maytal Capital, a private equity investment and advisory firm he founded, as well as an Operating Partner at Revival Healthcare Capital. John Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations. Until June 2019 he served as Senior Assurance Partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors. Shlomo Yanai has more than 15 years of corporate leadership experience, primarily in the pharmaceutical industry. He most recently served as President and CEO at Teva Pharmaceutical Industries Ltd., from 2007 to 2012, where he increased revenues from $8.4 billion in 2006 to $18.3 billion in 2011, and net profit from $1.9 billion to $4.4 billion over the same time period. Amneal also announced that Jean Selden Greene has retired from the Amneal Board, effective as of December 14, 2019.